



## Click chemistry based multicomponent approach in the synthesis of spirochromenocarbazole tethered 1,2,3-triazoles as potential anticancer agents



Pramod V. Chavan<sup>a</sup>, Uday V. Desai<sup>a,\*</sup>, Prakash P. Wadgaonkar<sup>b</sup>, Savita R Tapase<sup>c</sup>, Kisan M. Kodam<sup>c</sup>, Amit Choudhari<sup>d</sup>, Dhiman Sarkar<sup>d,\*</sup>

<sup>a</sup> Department of Chemistry, Shivaji University, Kolhapur 416 004, India

<sup>b</sup> Polymer Science and Engineering Division, CSIR, National Chemical Laboratory, Pune 411 008, India

<sup>c</sup> Biochemistry Division, Department of Chemistry, Savitribai Phule Pune University, Pune 411007, India

<sup>d</sup> Combi – Chem. Bio-Resource Centre, CSIR National Chemical Laboratory, Pune 411 008, India

### ARTICLE INFO

#### Keywords:

Click chemistry  
1,2,3-Triazolylspirochromenocarbazole  
Anticancer  
Cytotoxicity  
Apoptotic assay  
Heterogeneous catalysis  
Multicomponent synthesis

### ABSTRACT

A series of spirochromenocarbazole tethered 1,2,3-triazoles were synthesized *via* click chemistry based one-pot, five component reaction between N-propargyl isatins, malononitrile, 4-hydroxycarbazole, aralkyl halides and sodium azide using cellulose supported CuI nanoparticles (Cell-CuI NPs) as the heterogeneous catalyst. Antiproliferative activity of all the synthesized compounds was investigated against panel of cancer cell lines such as MCF-7, MDA-MB-231, HeLa, PANC-1, A-549, and THP-1. Many of the synthesized compounds exhibited good anti-proliferative activity against breast (MCF-7 and MDA-MB-231) and cervical (HeLa) cancer cells with IC<sub>50</sub> values less than 10 μM. In case of MCF-7 cells, among the nine compounds that showed good anti-proliferative activity, compounds **6f** and **6j** were found to be highly potent (IC<sub>50</sub> = 2.13 μM and 4.80 μM, respectively). In case of MDA-MB-231, three compounds (**6k**, **6j** and **6s**) showed antiproliferative activity amongst which **6k** was the most potent one (IC<sub>50</sub> = 3.78 μM). On the other hand, in cervical cancer HeLa cells, compounds **6b**, **6g**, **6s** and **6u** showed excellent antiproliferative activity (IC<sub>50</sub> = 4.05, 3.54, 3.83, 3.35 μM, respectively). All the compounds were found to be nontoxic to the human umbilical vein endothelial cells (HUVECs). AO and EtBr staining and fluorescence microscopy studies of the active compounds (IC<sub>50</sub> < 5 μM) suggested that these compounds induce cell death by apoptosis.

### 1. Introduction

Cancer is a multifaceted disease caused due to uncontrolled growth of abnormal cells and after cardiovascular disease it is the most common cause of death worldwide [1,2]. While great strides have been made in the treatment of cancer, it still continues to be a major health concern [3]. In the treatment of almost all types of cancers, after surgery the use of chemotherapeutics that inhibit hyper proliferation of cancer cells is routinely practised [4,5]. However, this therapy is plagued with the side effects that include off-target toxicity and drug resistance [6]. Consequently, the discovery of new drugs that can inhibit proliferation or induce death of cancer cells without disturbing normal cells is highly desirable.

Many heterocyclic compounds containing isatin, thiazolidinone, benzimidazole, oxindole, β-carboline, etc. as the structural motif serve

as potential anticancer agents [7–10]. In the recent years based upon the hypothesis that, the molecules synthesized by the combination of heterocyclic pharmacophores can have enhanced biological potential [11,12] the most attractive strategy in the design of new anticancer agents involves combination of pharmacophoric templates through molecular hybridization [13–16]. With all these concepts in mind and our continued interest in multicomponent synthesis as well as in the synthesis of hybrid molecules [17–20], we planned to undertake the synthesis of novel hybrid molecules as potential anti-cancer agents.

Carbazoles are probably the most widely spread nitrogen heterocycles in nature [21,22]. Especially aryl and hetero annulated carbazoles like pyridocarbazoles, indolocarbazoles, pyrrolocarbazoles, pyranocarbazoles, etc. are distributed in numerous natural products with diverse biological activities [23–26]. The hetero annulated carbazoles of synthetic origin have attracted growing attention these days due to

\* Corresponding authors.

E-mail addresses: [uvdchem2011@gmail.com](mailto:uvdchem2011@gmail.com) (U.V. Desai), [d.sarkar@ncl.res.in](mailto:d.sarkar@ncl.res.in) (D. Sarkar).

<https://doi.org/10.1016/j.bioorg.2019.01.070>

Received 8 April 2018; Received in revised form 25 January 2019; Accepted 30 January 2019

Available online 08 February 2019

0045-2068/ © 2019 Elsevier Inc. All rights reserved.





Fig. 1. Biologically active compounds containing 1,2,3 triazole, isatin and carbazole moieties.

their antidiabetic, antimicrobial, antioxidant, anticancer, anti-tubercular as well as anticonvulsant activities [27–32].

Alike carbazole, 1,2,3-triazole is another medicinally privileged scaffold serving as a key structural feature in many bioactive molecules as well as pharmaceuticals [33]. Many molecules containing 1,2,3-triazole as the structural motif are known to possess anti-tubercular, anti-fungal, anti-allergic, anti-viral, anti-tumor, anti-malarial as well as anti-HIV properties [34–42] while many 1,2,3-triazole conjugates have already been reported to exhibit potent anticancer activity [43–49]. For instance, carboxyamidotriazole is a commercially available anticancer drug that contains 1,2,3-triazole as the structural unit [50]. On the other hand, isatin is a medicinally privileged scaffold that has led to the generation of large number of structurally related compounds that exhibit anticancer agents [51]. Representative biologically potent

compounds containing carbazole, triazole and isatin are shown in Fig. 1. Considering the biological potential of compounds containing carbazole, isatin as well as 1,2,3-triazole as the structural units, we surmised that hybrid molecules containing all these structural units may possess enhanced anticancer activity.

We have earlier reported cellulose supported CuI nanoparticles (Cell-CuI NPs) as a heterogeneous catalyst in the synthesis of 1,2,3-triazoles [52] and as an extension to that work, we have also reported the synthesis of spirochromene tethered 1,2,3-triazoles, **8** (Scheme 1A) by the reaction between N-propargyl isatin, malononitrile, dimedone, aralkyl halide and sodium azide. The synthesized compounds were found to exhibit potential anti-tubercular activity [20]. Based on these results and the focused literature survey on biological potential of compounds containing pyranocarbazole, 1,2,3-triazole as well as isatin



Scheme 1. One-pot, five component synthesis of spirochromenocarbazole tethered 1,2,3-triazoles.

**Table 1**  
Cell-CuI NPs catalyzed synthesis of spiro [indoline-3,4'-pyrano[3,2-c] carbazole tethered 1,2,3-triazoles.<sup>a</sup>

Entry	N-propargyl isatin (1)	Aralkyl or alkyl bromide (4)	Product (6)	Time (h)	Yield (%)	M.P. (°C)
1	1a	4a	6a	3	92	160–162
2	1a	4b	6b	3	90	185–187
3	1a	4c	6c	3	87	190–192
4	1a	4d	6d	4	89	195–197
5	1a	4e	6e	4	84	168–170
6	1a	4f	6f	4	87	178–180
7	1a	4g	6g	4	85	160–162
8	1a	4h	6h	5	83	176–178
9	1a	4i	6i	3	91	165–167
10	1a	4j	6j	5	86	158–160
11	1a	4k	6k	5	84	156–157
12	1b	4a	6l	3	92	197–199
13	1b	4b	6m	4	87	160–165
14	1b	4c	6n	3	89	190–192
15	1b	4d	6o	3	90	187–189
16	1c	4a	6p	4	85	182–184
17	1c	4b	6q	3	87	202–204
18	1c	4c	6r	4	88	190–192
19	1c	4d	6s	5	86	185–187
20	1d	4a	6t	4	87	168–170
21	1d	4b	6u	4	85	175–177
22	1d	4c	6v	5	83	180–182
23	1d	4d	6w	4	81	170–172
24	1e	4a	6x	3	88	201–203
25	1e	4b	6y	4	86	218–220
26	1e	4c	6z	4	89	205–208
27	1e	4d	6aa	4	84	190–192

<sup>a</sup> Reaction conditions: N-propargyl isatin, malononitrile, 4-hydroxycarbazole, aralkyl bromide (1 mmol, each) and NaN<sub>3</sub> (1.1 mmol), Cell-CuI (7 mol %), DMF – water – (1:2, v/v, 6 mL), 70 °C.

as the structural units (Fig. 1) we speculated that, replacement of dimedone component from the aforementioned multicomponent reaction by 4-hydroxycarbazole would furnish spirochromenocarbazole tethered 1,2,3-triazoles with anti-cancer activity. As an outcome of this philosophy, herein we report the synthesis of spirochromenocarbazole tethered 1,2,3-triazoles by one-pot, five component reaction between N-propargyl isatins, malononitrile, 4-hydroxycarbazole, aralkyl halides and sodium azide using cellulose supported CuI nanoparticles (Cell-CuI NPs) as the catalyst. The studies on their anticancer activity have also been described (Scheme 1B).

## 2. Result and discussion

### 2.1. Chemistry

The synthetic route was initiated with the preparation of N-propargyl isatins. Various substituted N-propargylated isatins were prepared by potassium carbonate catalyzed propargylation of isatins with propargyl bromide using DMF as solvent and TBAB as the phase transfer catalyst. We then turned our attention to examine the first model reaction for the synthesis of 6a. In this regard, we decided to employ the reaction conditions described earlier by us for the synthesis of

**Table 2**  
Anticancer activity data of spirochromenocarbazole tethered 1,2,3-triazoles on various human cancer cell lines.

Sr. No.	Compound Codes	MCF-7 Cells IC <sub>50</sub> (μM) ± SD	MDA-MB-231 IC <sub>50</sub> (μM) ± SD	HeLa Cell IC <sub>50</sub> (μM) ± SD	HUVEC IC <sub>50</sub> (μM) ± SD
1	6a	7.02 ± 0.93	17.25 ± 0.08	12.35 ± 0.17	> 100
2	6b	25.56 ± 2.12	12.74 ± 2.32	4.05 ± 0.69	> 100
3	6c	14.37 ± 0.95	13.33 ± 0.48	> 100	> 100
4	6d	> 100	> 100	> 100	> 100
5	6e	25.51 ± 0.32	37.66 ± 0.55	> 100	> 100
6	6f	2.13 ± 0.16	24.89 ± 0.74	> 100 ± 1.6	> 100
7	6g	6.31 ± 0.63	14.86 ± 0.12	3.54 ± 1.24	> 100
8	6h	6.97 ± 0.83	23.66 ± 1.02	15.88 ± 1.12	> 100
9	6i	18.00 ± 0.32	41.64 ± 0.04	10.83 ± 0.6	> 100
10	6j	4.80 ± 0.25	8.39 ± 1.84	9.21 ± 0.34	> 100
11	6k	51.16 ± 0.53	3.78 ± 0.74	61.89 ± 2.53	> 100
12	6l	> 100	> 100	> 100	> 100
13	6m	> 100	> 100	> 100	> 100
14	6n	62.74 ± 0.17	71.26 ± 1.18	75.81 ± 0.61	> 100
15	6o	42.50 ± 0.67	60.82 ± 0.38	13.25 ± 0.37	> 100
16	6p	9.40 ± 0.36	42.37 ± 0.55	32.49 ± 0.15	> 100
17	6q	7.06 ± 0.35	30.33 ± 3.8	61.29 ± 1.67	> 100
18	6r	6.57 ± 0.26	25.38 ± 0.69	42.77 ± 0.22	> 100
19	6s	14.81 ± 0.61	9.35 ± 1.10	3.83 ± 0.51	> 100
20	6t	9.72 ± 0.89	99.59 ± 0.55	> 100	> 100
21	6u	> 100	75.01 ± 0.28	3.35 ± 0.17	> 100
22	6v	> 100	63.08 ± 2.14	37.87 ± 4.11	> 100
23	6w	> 100	> 100	> 100	> 100
24	6x	88.85 ± 0.06	> 100	59.12 ± 0.32	> 100
25	6y	> 100	> 100	> 100	> 100
26	6z	16.54 ± 0.51	27.88 ± 1.67	7.80 ± 0.58	> 100
27	6aa	23.69 ± 1.45	50.32 ± 0.59	94.77 ± 0.20	> 100
28	Paclitaxel	0.0026 ± 0.00	0.1 ± 0.07	0.0061 ± 0.00	> 10
29	Doxorubicin	4.63 ± 0.41	0.55 ± 0.01	2.66 ± 0.32	> 10

spirochromene tethered 1,2,3-triazoles [20]. Accordingly, to a well stirred solution of N-propargyl isatin, malononitrile, 4-hydroxycarbazole, benzyl bromide (1 mmol, each) and sodium azide (1.1 mmol) in DMF: H<sub>2</sub>O (1: 2, v/v) was added Cell-CuI NPs (200 mg, 7.4 mol% CuI) as the catalyst. The reaction mixture was heated with stirring at 70 °C and the progress of the reaction was monitored by TLC. Upon completion of the reaction followed by work-up, it was truly gratifying to notice the formation of expected spirochromenocarbazole tethered 1,2,3-triazole, **6a**, in excellent yield (92%). So as to examine the scope of the developed protocol, few reactions were then performed by replacement of benzyl bromide component from the model reaction with various aralkyl as well as alkyl bromides. In each case, respective spirochromenocarbazole tethered 1,2,3-triazole was obtained in acceptable yield (Table 1, entry **6b** to **6k**). So as to explore generality of the reaction conditions, keeping malononitrile, 4-hydroxycarbazole and sodium azide components from the model reaction same, various N-propargylated isatins (**1b–1e**) were allowed to react with various aralkyl bromides (**4a–4d**). Once again, the reactions furnished expected spirochromenocarbazole tethered 1,2,3-triazoles in decent yields (Table 1, entry **6l** to **6aa**).


After the library synthesis of spirochromenocarbazole tethered 1,2,3-triazoles, **6a–6aa**, it was planned to undertake screening of the synthesized compounds for their anti-cancer activity. In this regard it was essential that the synthesized compounds are free from copper content and the same in the synthesized compounds is possible if the catalyst undergoes leaching under the employed reaction conditions. Hence, it was decided to examine the leaching behavior of the catalyst. Thus, upon completion of the model reaction, the reaction mixture was diluted with water and resultant solid was filtered. Resultant filtrate was analyzed for its copper content by AAS. Results being negative it was inferred that the synthesized compounds are suitable for the biological assay.

## 2.2. Biological evaluation

All the synthesized compounds were evaluated for their anti-proliferative activity against a panel of six human cancer cells namely MCF-7 and MDA-MB-231 (Breast Carcinoma), HeLa (Cervical Carcinoma), PANC-1 (Pancreas Carcinoma), A-549 (Lung Carcinoma) and THP-1 (acute monocytic leukemia). In addition, non-cancerous HUVEC cell line was chosen to compare the effect of synthesized compounds between cancerous and non-cancerous cells. Paclitaxel and Doxorubicin were used as a positive control.

Cells were treated with different concentration (0–100 μg/ml) of all the synthesized compounds and incubated for 48 h. Screening studies revealed that, most of the compounds were active against breast cancer cells MCF-7 and MDA-MB-231 (ER, PR positive) and cervical cancer cells, HeLa (HPV-positive) with IC<sub>50</sub> values in low micro-molar range (> 10 μM). However, they did not exhibit any cytotoxicity against PANC-1, A-549 and THP-1 cancer cell lines (SI, Table 1). IC<sub>50</sub> values of all the synthesized compounds with respect to MCF-7, MDA-MB-231 and HeLa cancer cell lines and one, normal HUVEC cell line, are summarized in Table 2.

Among the synthesized compounds, **6a**, **6f**, **6g**, **6h**, **6j**, **6p**, **6q**, and **6r** were notably active against MCF-7 cells with IC<sub>50</sub> values in the range 2.1–7.06 μM. Especially compounds **6f** and **6j** were highly active (IC<sub>50</sub> = 2.13 and 4.80 μM, respectively). Similarly, compounds **6j**, **6k** and **6s** showed very good activity against MDA-MB-231 cells with IC<sub>50</sub> values in the range 3.78–9.35 μM and among these **6k** showed excellent activity (IC<sub>50</sub> = 3.78 μM). On the other hand, compounds **6b**, **6g**, **6j**, **6s**, **6u** and **6z** showed very good activity against HeLa cells with IC<sub>50</sub> values in the range 3.35–9.2 μM and among these compound **6u** was noticed to be the most active one (IC<sub>50</sub> = 3.35 μM). During the screening studies it was noticed that, compound **6j**, shows pronounced activity against all the aforementioned cell lines with IC<sub>50</sub> in the range



**Fig. 2.** Fluorescent images showing apoptosis induced by selected chromenocarbazole tethered 1,2,3-triazoles derivatives in (A) MCF-7, (B) MDA MB 231 and (C) HeLa cells. Control and treated cells were stained with Acridine orange (AO)/Ethidium bromide (EtBr); and the staining pattern was monitored by The ArrayScan™ 4.0 system. For detection of AO (green) (Panel I) and EtBr (red) (Panel II), mercury-xenon lamp was excited at 488 nm and 590 nm, respectively. Panel III represents the merge images.

4.8–9.2  $\mu\text{M}$ . In order to check the biocompatibility of the synthesized compounds towards normal cell, MTT assay was also performed with HUVEC cell and it was truly delighting that all the synthesized compounds exhibited biocompatibility above 100  $\mu\text{M}$  concentrations (Table 2). These results reveal that, synthesized compounds are non-toxic to noncancerous cell line.

### 2.3. Structure activity relationship:

So as to arrive at the relationship between the structures of the synthesized compounds and their anticancer activity it would be rational to categorize these compounds in to two groups: (i) Those prepared using N-propargyl isatin (6a-6k) and, (ii) prepared using substituted N-propargyl isatins (6l-6aa). Among the twenty seven




Fig. 2. (continued)

Table 3

Percent of viable, apoptotic and necrotic cell population as measured by AO/EB fluorescent staining studies.

	Viable	Apoptotic	Necrotic
<i>MCF-7</i>			
Control	89.5 ± 2.3	5.4 ± 1.4	5.1 ± 1.8
<b>6f</b>	42.0 ± 2.3	14.3 ± 1.4	38.6 ± 1.8
<b>6j</b>	49.6 ± 10.2	43.2 ± 2.4	7.2 ± 4.1
<i>MDA-MB-231</i>			
Control	92.8 ± 1.8	5.6 ± 1.3	1.6 ± 0.01
<b>6k</b>	42.8 ± 2.2	36.1 ± 1.8	21.1 ± 2.1
<i>HeLa</i>			
Control	97.8 ± 1.2	1.4 ± 0.01	0.8 ± 0.2
<b>6s</b>	41.4 ± 2.8	46.2 ± 2.3	12.4 ± 7.2

compounds screened for their anti-cancer activity, nine compounds (**6a**, **6f**, **6g**, **6h**, **6j**, **6p**, **6q**, **6r** and **6t**) were prominently active against MCF-7 cells, six compounds (**6b**, **6g**, **6j**, **6u**, **6s** and **6z**) showed excellent activity against HeLa cells and only three compounds (**6j**, **6k** and **6s**) showed good activity against MDA-MB-231 cells. It is worthy to note that among these eighteen compounds, ten active compounds [**6a**, **6b**, **6f**, **6h**, **6k**, **6g** (two cell lines) and **6j** (three cell lines)] were prepared using N-propargyl isatin as the starting compound. On the other hand, remaining eight compounds (**6p**, **6q**, **6r**, **6s**, **6t**, **6u**, and **6z**) were prepared using 5-chloro, 5-bromo, 5-fluoro and 5-methyl-N-propargyl isatin as the starting materials. Furthermore out of these eight compounds, five compounds [**6p**, **6q**, **6r**, **6s** (two cell lines)] were prepared using 5-bromo-N-propargyl isatin as the starting material, the remaining three compounds **6t** and **6u** were prepared using 5-fluoro-N-propargyl isatin while **6z** was prepared using 5-methyl-N-propargyl isatin. On analysis of this data it could broadly be concluded that, most active compounds are derived from N-propargyl isatin and 5-bromo-N-propargyl isatin whereas substitution of chloro, fluoro as well as methyl group on N-propargyl isatin does not assist in improvement of anticancer activity. As regards the effect of aralkyl or alkyl bromide component on anticancer activity is concerned it was noticed that, compounds prepared using benzyl bromides bearing electron-withdrawing groups (**6f** and **6g**) were more potent than those prepared using benzyl bromide (**6a**) or the one bearing electron-donating group (**6h**) and the one prepared using aliphatic long chain bromide, **6k**, was active against Breast as well as cervical cancer cells.

In summary, in the multicomponent synthesis of

spirochromenocarbazole tethered 1,2,3-triazoles as anticancer agents, the use of unsubstituted *n*-propargyl isatin, **1a**, in combination with benzyl bromides bearing electron-withdrawing group, **4f** and **4g**, or aliphatic bromides, **4j** and **4k** has furnished the compounds with excellent anticancer activity against MCF-7 cells. In case HeLa cells, excellent anticancer activity was noticed by four compounds (**6b**, **6g**, **6s** and **6u**) and it was interesting to note that, out of these four compounds three compounds (**6g**, **6s** and **6u**) that showed excellent and comparable activity were containing fluorine or bromine substituent in them. Thus, presence of halogen substituent may be responsible for the improvement of anticancer activity against HeLa cells.

Based upon these studies we propose that, there certainly exists scope for the synthesis novel spirochromenocarbazole tethered 1,2,3-triazoles with improved anticancer activity by using difluoro or dibromo isatin in combination with 4-triflorobenzyl bromide, 4-nitrobenzyl bromide and aliphatic long chain bromides.

#### 2.4. Apoptosis assays

To gain insight of the mechanisms by which the tested compounds reduced proliferation of breast cancer cells, the compounds showing significant anti-proliferative activity were assessed for cell death. Thus, MCF-7, MDA-MB-231 and HeLa cells were treated at the concentrations in the range of IC<sub>50</sub> for 48 h and after staining with acridine orange and ethidium bromide (AO/EB) were assessed by ArrayScan™ 4.0 High content screening system. Depending upon the overall morphological characteristics and the cell membrane integrity, the cells were distinguished from one another as necrotic, apoptotic or live cells. Apoptotic cells containing apoptotic bodies (condensed nucleus) were observed as yellow/orange colored cells while the necrotic cells were observed as red colored cells. Interestingly, compared to compounds **6a**, **6g**, **6h**, **6p**, **6q**, **6r** and **6t** (SI Fig. 1) the number of apoptotic and necrotic events were significantly high in case of **6f** and **6j** treated MCF-7 cells (Fig. 2A). Similarly, compared to compounds **6j** and **6s** (SI, Fig. 2), **6k** treated MDA MB-231 cells showed higher apoptotic and necrotic population (Fig. 2B). On the other hand, in case of HeLa cells, compared to **6b**, **6g**, **6j**, **6u** and **6z** (SI, Fig. 3), **6s** treated cells (Fig. 2C) showed significant increase in apoptotic events. However, the morphological assessment of **6b**, **6g**, **6j**, **6u**, **6z** treated HeLa Cells revealed a decrease in cell number by cell cycle arrest. The results of the most active compounds in the respective cell line are summarized in Table 3 and the same of all the compounds are summarized in SI, Table 3. The results obtained are in agreement with the results of MTT assay. In

summary, we could assume that under the applied conditions apoptotic cell death was the major cause of reduced proliferation of the breast cancer cells but not in the cervical cancer cells.

## 2.5. Conclusions

Taking clues from the structures of the compounds with proven biological activities and our experiences in click chemistry as well as multicomponent reactions, studies were undertaken on the synthesis of novel anticancer agents. During the studies, we have designed and synthesized for the first time a series of spirochromenocarbazole tethered 1,2,3-triazoles by one-pot, five component condensation reaction between N-propargyl isatins, malononitrile, 4-hydroxycarbazole, alkyl/arylalkyl halides and sodium azide using cellulose supported CuI nanoparticles (Cell-CuI NPs) as the heterogeneous catalyst. Simple experimental procedure, wide scope and reusability of the catalyst are the main merits of the developed protocol. The synthesized compounds were found to be selectively cytotoxic against breast (MCF-7, MDA-MB-231) and cervical (HeLa) cancer cells. Among all screened compounds, **6f**, **6k**, **6g**, **6s** and **6u** showed excellent activity towards MCF-7, MDA-MB-231 and HeLa cancer cell lines. Especially compound **6j** showed good activity for all three cancer cell lines. The synthesized compounds being nontoxic towards normal cells, they may be useful towards specific cancer cell lines. Furthermore, AO/EB staining suggested that under the applied conditions apoptotic cell death was the major cause of reduced proliferation of the breast cancer cells but not in the cervical cancer cells.

## 3. Experimental

### 3.1. General

Isatins (Aldrich), benzyl halides (Aldrich), sodium azide (S. D. Fine-Chem. Limited, Mumbai), 4-hydroxycarbazole, malononitrile, copper (I) iodide (Spectrochem, Mumbai) and microcrystalline cellulose (SRL, Mumbai) were used, as received. The catalyst Cell-CuI NPs was prepared according to the procedure developed and reported by us earlier [20]. Melting points were recorded using Kumar melting point apparatus. IR spectra were recorded as neat using Thermo Scientific Nicolet S10 FT-IR Spectrometer. <sup>1</sup>H NMR (300 MHz) and <sup>13</sup>C NMR (75 MHz) spectra were recorded using Bruker Avance – II spectrometer. High resolution mass spectra (HRMS) were recorded using Thermo Scientific Q-Exactive, Accela 1250 pump, instrument.

### 3.2. Representative procedure for the preparation of N-propargylation of isatin

Isatin (1 mmol), potassium carbonate (1 mmol), propargyl bromide (1.3 mmol) and TBAB (0.05 mmol) were placed in a round bottom flask. DMF (3 mL) was added and the reaction mixture was stirred at room temperature for 24 h. After completion of reaction (TLC), crushed ice was added and stirring was continued for 15 min more. Resultant solid was filtered and washed with water (4 × 5 mL). It was dried in air and recrystallized from ethanol.

### 3.3. Representative procedure for one-pot synthesis of spirochromenocarbazole tethered 1,2,3-triazoles[1,4-disubstituted-1,2,3-triazolyl spiroindoline pyrano [3,2-c] carbazoles, **6a-6aa**]

N-propargyl isatin (1 mmol), malononitrile (1 mmol), 4-hydroxycarbazole (1 mmol), benzyl bromide (1 mmol), and sodium azide (1.1 mmol) were placed in a round bottom flask. DMF-Water (1: 2, 6 mL, v/v) and cellulose-CuI NPs catalyst (0.2g) were added and the reaction mixture was heated at 70 °C. After completion of the reaction (TLC), the reaction mixture was filtered and the filter was washed with ethyl acetate (4 × 10 mL). The organic extract was washed with water,

brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of solvent under vacuum furnished corresponding 1,4-disubstituted-1,2,3-triazolyl spiroindoline pyrano[3,2-c] carbazole as a solid product. The resultant solid was successively washed using a mixture of hexane – chloroform (80:20 v/v), and dried. The resultant product did not require any further purification. The recovered catalyst was washed with acetone, dried in air. Reusability studies showed that the catalyst can be reused for five consecutive runs without significant loss in its activity.

## 3.4. Biological methods

### 3.4.1. Cytotoxicity assay

Six human cancer cell lines, MCF-7 and MDA-MB-231, HeLa, PANC-1, A-549, THP-1 were used to check the cytotoxicity of the synthesized compounds. The cell lines were obtained from National Center for Cell Science (NCCS), Pune and maintained in T25 flasks with 10% (v/v) fetal bovine serum (FBS) containing Dulbecco's Modified Eagle Medium (DMEM). HUVECs cells were purchased from Life Technologies and maintained in basal medium M200 (Life Technologies) containing 10% FBS and growth factors (LSGS, Life Technologies). Cell line containing T25 flasks were maintained at 37 °C under 5% CO<sub>2</sub> and 95% air in a humidified atmosphere. Medium were replaced twice a week.

The cytotoxicity of the synthesized compounds was tested against the mentioned cell lines by using modified MTT assay [53]. Briefly, cells were seeded at the density of  $1 \times 10^4$  cells/mL in a 96 well plate. The plates were incubated overnight into CO<sub>2</sub> incubator (37 °C under 5% CO<sub>2</sub> and 95% air in a humidified atmosphere) to adhere the cells. Next day, cells were treated with different concentration of test compounds (100–0 µg/ml) and incubated for additional 48 h. Post incubation, cell medium was replaced with MTT (0.5 mg/mL) – PBS medium and incubated for 2–4 h to form Formazan crystals. The crystals were solubilized by addition of acidified isopropanol. The optical density was read on a micro plate reader at 570 nm filter against a blank prepared from cell-free wells. Absorbance given by cells treated with the vehicle alone was taken as 100% cell growth. IC<sub>50</sub> and MIC values were calculated by using Origin Pro software. The viability and growth in the presence of test material is calculated by using the following formula: Percent cytotoxicity = [(average absorbance of control – absorbance of compound)/(absorbance of control – absorbance of blank)] × 100, where control is the culture medium with cells and DMSO while blank is the culture medium without cells. Paclitaxel and Doxorubicin were used as a positive control.

### 3.4.2. Morphological assessment by acridine orange and ethidium bromide double staining

The dual-fluorescence staining using acridine orange (AO) and ethidium bromide (EtBr) is a nuclear staining method used to assess apoptotic cell morphology. Stain AO is able to permeate into both live and dead cells to stain all the nucleated cells and excite green fluorescence, while stain EtBr enters only into dead cells with damaged membranes and generates red fluorescence. Thus, late apoptotic and necrotic cells take up both stains. Briefly, MCF-7, MDA-MB-231 and HeLa cells were seeded at the density of  $1 \times 10^4$  cells/mL in a 96 well plate. The plates were incubated overnight into CO<sub>2</sub> incubator. Next day, the cells were treated with IC<sub>50</sub> concentration of test compounds for additional 48 h. Post incubation, cell medium was replaced with AO and EtBr solution mixture (1 part each of 10 µg mL<sup>-1</sup> of AO and EtBr in PBS) and examined under Array Scan VTI HCS 600-type high content live cell imaging system. The Fluorescence microphotographs in the green, and red channels of at least 20 fields were acquired in each well with a 20X objective, corresponding to at least 2000 cells counted. An analysis of the fluorescence intensity was performed for AO and EtBr stained samples by the HCS Assay Scan software.

### 3.4.3. Spectral data

All the synthesized compounds are new and were fully

characterized by spectral methods.

**2-Amino-4,7-dihydro-1'((1-(benzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano [3,2-c]carbazole-3-carbonitrile, 6a:** Off-white solid; M.P.: 160–162 °C; IR (KBr): 3310, 3187, 2927, 2190, 1708, 1652, 1607, 1398, 1338, 1098, 748 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 4.97 (m, 2H, indolyl-CH<sub>2</sub>), 5.58 (s, 2H, benzylic-CH<sub>2</sub>), 6.35 (br s, 1H, Ar-H), 7.04 (s, 1H, Ar-H), 7.14 (d, 2H, J = 8.4 Hz, Ar-Hs), 7.21 (d, 1H, J = 7.8 Hz, Ar-Hs), 7.29 (m, 3H, Ar-Hs), 7.34–7.42 (m, 4H, Ar-Hs), 7.45 (d, 2H, J = 7.2 Hz, Ar-Hs), 7.51 (d, 1H, J = 8.1 Hz, Ar-H), 7.59 (s, 2H, NH<sub>2</sub>), 8.08 (s, 1H, triazolyl-H), 8.58 (d, 1H, J = 7.8 Hz, Ar-H), 11.55 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.70, 50.37, 53.31, 54.55, 108.50, 109.51, 110.04, 110.59, 111.42, 119.25, 119.74, 120.65, 123.68, 128.31, 128.59, 129.21, 129.39, 130.20, 136.41, 140.08, 140.77, 142.47, 142.76, 144.44, 161.86, 177.87 ppm; HRMS: mass calculated for [C<sub>33</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>]: 550.1991 [M + H]<sup>+</sup> and 572.1811 [M + Na]<sup>+</sup>; obs. mass: 550.1986 [M + H]<sup>+</sup> and 572.1805 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c] carbazole-3-carbonitrile, 6b:** cream colored solid; M.P.: 185–187 °C; IR (KBr): 3308, 3190, 2928, 2195, 1710, 16525, 1609, 1390, 1335, 1094, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 2.26 (s, 3H, Ar-CH<sub>3</sub>), 5.10 (m, 2H, indolyl-CH<sub>2</sub>), 5.18–5.56 (m, 2H, benzylic-CH<sub>2</sub>), 6.37 (d, 1H, J = 8.4 Hz, Ar-H), 7.06 (d, 2H, J = 8.4 Hz, Ar-Hs), 7.13 (m, 4H, Ar-Hs), 7.19 (d, 2H, J = 8.1 Hz, Ar-Hs), 7.24 (d, 1H, J = 7.5 Hz, Ar-H), 7.34 (d, 1H, J = 7.8 Hz, Ar-H), 7.42 (d, 1H, J = 7.8 Hz, Ar-H), 7.47–7.51 (m, 1H, Ar-H), 7.54 (br s, 2H, NH<sub>2</sub>), 8.02 (s, 1H, triazolyl-H), 8.57 (d, 1H, J = 7.8 Hz, Ar-H), 11.55 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 21.14, 35.70, 50.37, 53.13, 54.50, 108.53, 109.51, 110.03, 110.60, 111.43, 119.25, 119.77, 120.64, 123.64, 123.93, 125.18, 126.30, 128.34, 129.41, 129.74, 133.34, 135.17, 137.96, 140.08, 140.78, 142.46, 142.71, 144.44, 161.87, 177.88 ppm; HRMS: mass calculated for [C<sub>34</sub>H<sub>25</sub>N<sub>7</sub>O<sub>2</sub>]: 564.2148 [M + H]<sup>+</sup> and 586.1968 [M + Na]<sup>+</sup>; obs. mass: 564.2142 [M + H]<sup>+</sup> and 586.1962 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6c:** yellow solid; M.P.: 190–192 °C; IR (KBr): 3317, 3190, 2915, 2198, 1714, 1625, 1610, 1398, 1331, 1092, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 4.98 (m, 2H, indolyl-CH<sub>2</sub>), 5.57 (br s, 2H, benzylic-CH<sub>2</sub>), 6.38 (d, 1H, J = 8.4 Hz, Ar-H), 7.07 (d, 2H, J = 8.4 Hz, Ar-Hs), 7.13 (d, 1H, J = 6 Hz, Ar-H), 7.18 (d, 2H, J = 8.7 Hz, Ar-Hs), 7.23–7.26 (m, 2H, Ar-Hs), 7.31–7.37 (m, 3H, Ar-Hs), 7.42–7.47 (m, 1H, Ar-H), 7.51 (d, 1H, J = 8.1 Hz, Ar-H), 7.57 (br s, 2H, NH<sub>2</sub>), 8.17 (s, 1H, triazolyl-H), 8.57 (d, 1H, J = 7.8 Hz, Ar-H), 11.54 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.70, 50.36, 52.50, 54.57, 108.51, 109.50, 110.03, 110.59, 111.42, 115.88, 116.16, 119.62, 119.73, 120.64, 123.67, 123.76, 123.84, 125.19, 126.27, 129.40, 130.59, 130.70, 132.63, 135.17, 140.08, 140.78, 142.48, 142.79, 144.45, 160.70, 161.85, 177.87 ppm; HRMS: mass calculated for [C<sub>33</sub>H<sub>22</sub>FN<sub>7</sub>O<sub>2</sub>]: 568.1897 [M + H]<sup>+</sup> and 590.1717 [M + Na]<sup>+</sup>; obs. mass: 568.1892 [M + H]<sup>+</sup> and 590.1711 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6d:** brown solid; M.P.: 195–197 °C; IR (KBr): 3317, 3190, 2915, 2198, 1714, 1625, 1610, 1398, 1331, 1092, 745 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 5.03–5.05 (m, 2H, indolyl-CH<sub>2</sub>), 5.59 (s, 2H, benzylic-CH<sub>2</sub>), 6.38 (d, 1H, J = 8.4 Hz, Ar-H), 7.07 (d, 2H, J = 8.1 Hz, Ar-Hs), 7.14 (d, 1H, J = 6.9 Hz, Ar-Hs), 7.21 (d, 2H, J = 7.5 Hz, Ar-Hs), 7.31–7.37 (m, 3H, Ar-Hs), 7.40–7.47 (m, 3H, Ar-Hs), 7.51 (d, 2H, J = 7.8 Hz, Ar-Hs), 7.58 (s, 2H, NH<sub>2</sub>), 8.10 (s, 1H, triazolyl-H), 8.57 (br s, 1H, Ar-H), 11.55 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.69, 50.36, 52.47, 54.58, 108.51, 109.50, 110.02, 110.59, 111.41, 119.20, 119.71, 120.65, 123.67, 123.87, 125.20, 126.25, 129.17, 129.38, 130.23, 133.28, 135.18, 135.42, 138.25, 140.08, 140.78, 142.49, 142.80, 144.45, 147.88, 161.84, 177.85 ppm; HRMS: mass calculated for [C<sub>33</sub>H<sub>22</sub>ClN<sub>7</sub>O<sub>2</sub>]: 584.1602 [M + H]<sup>+</sup> and 606.1422

[M + Na]<sup>+</sup>; obs. mass: 584.1596 [M + H]<sup>+</sup> and 606.1416 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(4-cyanobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano [3,2-c]carbazole-3-carbonitrile, 6e:** brown solid; M.P.: 168–170 °C; IR (KBr): 3313, 3183, 2968, 2189, 1987, 1714, 1653, 1608, 1365, 1340, 1214, 1051, 749 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 5.05–5.06 (br s, 2H, indolyl-CH<sub>2</sub>), 5.72 (s, 2H, benzylic-CH<sub>2</sub>), 6.39 (d, 1H, J = 8.4 Hz, Ar-H), 7.07 (d, 1H, J = 7.8 Hz, Ar-H), 7.14 (d, 1H, J = 7.9 Hz, Ar-H), 7.2 (m, 2H, Ar-Hs), 7.32 (d, 1H, J = 7.2 Hz, Ar-H), 7.39–7.47 (m, 4H, Ar-Hs), 7.51 (d, 1H, J = 8.1 Hz, Ar-H), 7.59 (s, 2H, NH<sub>2</sub>), 7.81 (d, 2H, J = 7.8 Hz, Ar-Hs), 8.17 (s, 1H, triazolyl-H), 8.57 (d, 1H, J = 7.8 Hz, Ar-H), 11.55 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.66, 50.36, 52.65, 54.54, 108.53, 109.47, 110.05, 110.58, 111.34, 111.43, 118.99, 119.21, 119.76, 120.63, 123.66, 123.89, 123.92, 124.36, 125.21, 126.28, 129.01, 129.42, 133.15, 135.17, 140.07, 140.78, 141.91, 142.47, 142.89, 144.45, 161.84, 177.89 ppm; HRMS: mass calculated for [C<sub>34</sub>H<sub>22</sub>N<sub>8</sub>O<sub>2</sub>]: 575.1944 [M + H]<sup>+</sup> and 597.1764 [M + Na]<sup>+</sup>; obs. mass: 575.1938 [M + H]<sup>+</sup> and 597.1758 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano [3,2-c]carbazole-3-carbonitrile, 6f:** brown solid; M.P.: 178–180 °C; IR (KBr): 3315, 3173, 2978, 2179, 1985, 1714, 1650, 1610, 1360, 1338, 1212, 1055, 750 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 5.06 (s, 2H, indolyl-CH<sub>2</sub>), 5.78 (s, 2H, benzylic-CH<sub>2</sub>), 6.41 (d, 1H, J = 8.4 Hz, Ar-H), 7.08–7.14 (m, 3H, Ar-Hs), 7.24 (d, 2H, J = 7.0 Hz, Ar-Hs), 7.32 (d, 1H, J = 7.5 Hz, Ar-H), 7.44–7.53 (m, 4H, Ar-Hs), 7.58 (s, 2H, NH<sub>2</sub>), 8.19 (s, 1H, triazolyl-H), 8.24 (br s, 2H, Ar-Hs), 8.57 (d, 1H, J = 7.8 Hz, Ar-H), 11.54 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.65, 50.36, 52.65, 54.54, 108.54, 109.47, 110.05, 110.58, 111.34, 111.43, 118.99, 119.74, 120.63, 123.66, 123.92, 124.32, 124.42, 125.22, 126.29, 129.33, 129.42, 133.15, 135.17, 140.07, 140.78, 141.91, 142.47, 142.89, 144.45, 161.84, 177.89 ppm; HRMS: mass calculated for [C<sub>33</sub>H<sub>22</sub>N<sub>8</sub>O<sub>4</sub>]: 595.1842 [M + H]<sup>+</sup> and 617.1662 [M + Na]<sup>+</sup>; obs. mass: 595.1837 [M + H]<sup>+</sup> and 617.1662 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(4-trifluoromethylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6g:** brown solid; M.P.: 160–162 °C; IR (KBr): 3315, 3173, 2978, 2179, 1985, 1714, 1650, 1610, 1360, 1338, 1212, 1055, 750 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 5.06 (s, 2H, indolyl-CH<sub>2</sub>), 5.72 (s, 2H, benzylic-CH<sub>2</sub>), 6.41 (d, 1H, J = 8.1 Hz, Ar-H), 7.08 (d, 2H, J = 7.8 Hz, Ar-Hs), 7.14 (br s, 1H, Ar-H), 7.24 (br s, 2H, Ar-Hs), 7.32 (d, 1H, J = 7.2 Hz, Ar-H), 7.46–7.50 (m, 3H, Ar-Hs), 7.51 (d, 1H, J = 7.8 Hz, Ar-H), 7.58 (s, 2H, NH<sub>2</sub>), 7.70 (d, 2H, J = 7.2 Hz, Ar-Hs), 8.17 (s, 1H, triazolyl-H), 8.57 (d, 1H, J = 7.5 Hz, Ar-H), 11.55 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.68, 50.38, 52.62, 54.59, 108.54, 109.50, 110.05, 110.60, 111.43, 119.23, 119.74, 120.64, 122.73, 123.67, 123.91, 124.29, 125.21, 126.07, 126.11, 126.28, 128.95, 129.31, 129.41, 135.19, 140.10, 140.79, 141.10, 142.49, 142.87, 144.46, 161.86, 177.90 ppm; HRMS: mass calculated for [C<sub>34</sub>H<sub>22</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub>]: 618.1865 [M + H]<sup>+</sup> and 640.1685 [M + Na]<sup>+</sup>; obs. mass: 618.1860 [M + H]<sup>+</sup> and 640.1679 [M + Na]<sup>+</sup>.

**2-Amino-4,7-dihydro-1'((1-(3,4,5-trimethoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6h:** brown solid; M.P.: 176–178 °C; IR (KBr): 3315, 3173, 2978, 2179, 1985, 1714, 1650, 1610, 1360, 1338, 1055, 750 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>): δ 3.57 (s, 3H, Ar-OCH<sub>3</sub>), 3.66 (s, 6H, 2xAr-OCH<sub>3</sub>), 5.03–5.06 (br s, 2H, indolyl-CH<sub>2</sub>), 5.49 (s, 2H, benzylic-CH<sub>2</sub>), 6.39 (d, 1H, J = 8.4 Hz, Ar-H), 6.55–6.68 (m, 3H, Ar-Hs), 7.04 (d, 1H, J = 8.4 Hz, Ar-H), 7.13 (d, 1H, J = 6.0 Hz, Ar-H), 7.17 (d, 1H, J = 7.8 Hz, Ar-H), 7.24 (d, 1H, J = 7.5 Hz, Ar-H), 7.28 (d, 1H, J = 7.5 Hz, Ar-H), 7.42 (d, 1H, J = 7.8 Hz, Ar-H), 7.51 (d, 1H, J = 8.4 Hz, Ar-H), 7.57 (s, 2H, NH<sub>2</sub>), 8.10 (s, 1H, triazolyl-H), 8.53 (d, 1H, J = 7.2 Hz, Ar-H), 11.70 (s, 1H, NH); <sup>13</sup>C NMR (75.4 MHz, DMSO-d<sub>6</sub>): δ 35.65, 50.38, 53.51, 56.26, 60.44, 105.70, 105.98, 108.48, 109.48, 110.00, 111.45, 119.27, 120.62, 123.67, 123.83, 123.87, 123.96, 125.79, 126.28, 129.33, 131.76, 131.84, 135.22, 137.62,

140.08, 140.76, 142.48, 142.69, 144.46, 153.03, 153.44, 161.81, 178.11 ppm; **HRMS**: mass calculated for  $[C_{36}H_{29}N_7O_5]^+$ : 640.2308  $[M + H]^+$  and 662.2128  $[M + Na]^+$ ; obs. mass: 640.2303  $[M + H]^+$  and 662.2122  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(carboethoxy)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6i**: brown solid; M.P.: 165–167 °C; **IR (KBr)**: 3313, 3186, 2926, 2190, 1985, 1739, 1650, 1608, 1518, 1459, 1367, 1214, 1098, 745  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  1.19 (t, 3H,  $J = 7.2$  Hz, CH<sub>3</sub>), 4.17 (q, 2H,  $J = 7.2$  Hz, CH<sub>2</sub>CH<sub>2</sub>), 5.07 (q, 2H,  $J = 39.3$  Hz, indolyl-CH<sub>2</sub>), 5.39 (s, 2H, COCH<sub>2</sub>), 6.37 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.05–7.53 (m, 8H, Ar-Hs), 7.60 (s, 2H, NH<sub>2</sub>), 8.07 (s, 1H, triazolyl-H), 8.57 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.56 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  14.39, 35.61, 50.37, 50.89, 54.52, 61.95, 108.59, 109.57, 110.06, 110.56, 111.41, 119.21, 119.73, 120.64, 123.67, 123.90, 125.17, 126.26, 129.37, 135.20, 140.06, 140.77, 142.47, 144.40, 161.87, 167.58, 177.89 ppm; **HRMS**: mass calculated for  $[C_{30}H_{23}N_7O_4]^+$ : 546.1890  $[M + H]^+$  and 568.1710  $[M + Na]^+$ ; obs. mass: 546.1884  $[M + H]^+$  and 568.1704  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(pentyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6j**: brown solid; M.P.: 158–160 °C; **IR (KBr)**: 3313, 3186, 2926, 2190, 1985, 1739, 1650, 1608, 1518, 1459, 1367, 1214, 1098, 745  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  0.80 (t, 3H,  $J = 7.2$  Hz, CH<sub>3</sub>), 1.09–1.26 (m, 4H, CH<sub>2</sub>), 1.74–1.78 (m, 2H, CH<sub>2</sub>), 4.31 (t, 2H,  $J = 6.9$  Hz, CH<sub>2</sub>), 5.04 (m, 2H, indolyl-CH<sub>2</sub>), 6.39 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.08 (m, 2H, Ar-Hs), 7.12–7.20 (m, 2H, Ar-Hs), 7.24 (d, 1H,  $J = 7.2$  Hz, Ar-H), 7.30 (d, 1H,  $J = 7.8$  Hz, Ar-H), 7.42 (d, 1H,  $J = 7.2$  Hz, Ar-H), 7.50 (d, 1H,  $J = 8.1$  Hz, Ar-H), 7.56 (s, 2H, NH<sub>2</sub>), 7.98 (s, 1H, triazolyl-H), 8.56 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.53 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  14.19, 21.90, 28.34, 29.70, 35.86, 49.84, 50.38, 108.51, 109.46, 110.05, 110.57, 111.42, 119.34, 119.76, 120.62, 123.41, 123.65, 123.88, 123.90, 125.16, 126.29, 129.37, 135.21, 140.06, 140.77, 142.39, 144.43, 161.82, 177.88 ppm; **HRMS**: mass calculated for  $[C_{33}H_{27}N_7O_2]^+$ : 530.2304  $[M + H]^+$  and 552.2124  $[M + Na]^+$ ; obs. mass: 530.2299  $[M + H]^+$  and 552.2118  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(secondarybutyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[indoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6k**: brown solid; M.P.: 156–158 °C; **IR (KBr)**: 3307, 3184, 2967, 2189, 1709, 1652, 1608, 1458, 1397, 1305, 1051, 746  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  0.63–0.70 (m, 3H, CH<sub>3</sub>), 1.43 (dd, 3H,  $J = 6.6$  and 6.1 Hz, CH<sub>3</sub>), 1.74–1.80 (m, 2H, CH<sub>2</sub>), 4.56 (sextet, 1H,  $J = 6.6$  Hz, CH), 5.04 (br s, 2H, indolyl-CH<sub>2</sub>), 6.38 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.07 (m, 2H, Ar-H), 7.15 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.19 (d, 2H,  $J = 7.2$  Hz, Ar-H), 7.31–7.36 (m, 1H, Ar-H), 7.44 (d, 1H,  $J = 7.2$  Hz, Ar-H), 7.50 (d, 1H,  $J = 7.8$  Hz, Ar-H), 7.59 (s, 2H, NH<sub>2</sub>), 7.99 (s, 1H, triazolyl-H), 8.57 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.54 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  10.56, 20.99, 29.92, 35.85, 50.39, 54.59, 58.50, 108.51, 109.43, 110.05, 110.58, 111.42, 119.37, 119.75, 120.64, 121.56, 123.66, 123.89, 123.91, 125.16, 126.28, 129.38, 135.27, 140.06, 140.78, 142.37, 142.37, 142.42, 144.45, 161.78, 177.89 ppm; **HRMS**: mass calculated for  $[C_{30}H_{25}N_7O_2]^+$ : 516.2148  $[M + H]^+$  and 538.1968  $[M + Na]^+$ ; obs. mass: 516.2142  $[M + H]^+$  and 538.1962  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(benzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-chloroindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6l**: brown solid; M.P.: 197–199 °C; **IR (KBr)**: 3307, 3184, 2967, 2189, 1709, 1652, 1608, 1458, 1397, 1305, 1051, 746  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  5.00 (s, 2H, indolyl-CH<sub>2</sub>), 5.49 (br s, 2H, benzylic-CH<sub>2</sub>), 6.34 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.00 (d, 2H,  $J = 8.4$  Hz, Ar-Hs), 7.11 (d, 2H,  $J = 8.4$  Hz, Ar-Hs), 7.17 (d, 2H,  $J = 8.4$  Hz, Ar-Hs), 7.23–7.33 (m, 4H, Ar-Hs), 7.36–7.38 (br s, 2H, NH<sub>2</sub>), 7.43 (d, 1H,  $J = 8.1$  Hz, Ar-H), 7.90 (br s, 1H, Ar-H), 8.00 (s, 1H, triazolyl-H), 8.50 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.30 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  35.85, 50.57, 53.62, 54.00, 108.33,

108.49, 110.80, 111.15, 111.25, 119.17, 119.57, 120.70, 123.43, 123.51, 123.63, 125.18, 125.96, 128.12, 128.34, 128.50, 129.03, 129.11, 135.71, 136.97, 140.03, 140.92, 140.99, 142.40, 144.44, 161.93, 177.59 ppm; **HRMS**: mass calculated for  $[C_{33}H_{22}ClN_7O_2]^+$ : 584.1602  $[M + H]^+$ ; obs. mass: 584.1596  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-chloroindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6m**: brown solid; M.P.: 160–165 °C; **IR (KBr)**: 3307, 3184, 2923, 2190, 1777, 1705, 1650, 1608, 1487, 1454, 1335, 1216, 1107, 749  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  2.26 (s, 3H, Ar-CH<sub>3</sub>), 4.99 (s, 2H, indolyl-CH<sub>2</sub>), 5.44 (s, 2H, benzylic-CH<sub>2</sub>), 6.36 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.03 (d, 2H,  $J = 8.7$  Hz, Ar-Hs), 7.11–7.15 (m, 4H, Ar-Hs), 7.18 (d, 1H,  $J = 7.5$  Hz, Ar-H), 7.26 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.35 (d, 2H,  $J = 7.2$  Hz, Ar-Hs), 7.44 (br s, 2H, NH<sub>2</sub>), 7.88 (d, 1H,  $J = 9.0$  Hz), 8.07 (s, 1H, triazolyl-H), 8.52 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.36 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  21.18, 35.91, 50.56, 53.44, 54.12, 108.33, 108.45, 110.80, 111.13, 111.20, 119.16, 119.53, 120.71, 123.29, 123.45, 123.63, 125.17, 125.93, 128.14, 128.26, 128.32, 129.07, 129.60, 132.64, 136.95, 137.99, 140.02, 140.92, 140.99, 144.45, 161.91, 177.55 ppm; **HRMS**: mass calculated for  $[C_{34}H_{24}ClN_7O_2]^+$ : 598.1758  $[M + H]^+$ ; obs. mass: 598.1753  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-chloroindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6n**: brown solid; M.P.: 190–192 °C; **IR (KBr)**: 3307, 3184, 2923, 2190, 1777, 1705, 1650, 1608, 1487, 1454, 1335, 1216, 1107, 749  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  5.04 (br s, 2H, indolyl-CH<sub>2</sub>), 5.58 (s, 2H, benzylic-CH<sub>2</sub>), 6.41 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.09–7.12 (d, 1H,  $J = 8.7$  Hz, Ar-H), 7.15–7.28 (m, 2H, Ar-Hs), 7.21–7.25 (m, 3H, Ar-Hs), 7.33 (d, 2H,  $J = 6.3$  Hz, Ar-Hs), 7.35 (d, 1H,  $J = 6.0$  Hz, Ar-H), 7.43 (d, 1H,  $J = 9.0$  Hz, Ar-H), 7.52 (d, 1H,  $J = 7.8$  Hz, Ar-H), 7.64 (s, 2H, NH<sub>2</sub>), 8.10 (s, 1H, triazolyl-H), 8.57 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.57 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  35.80, 50.62, 52.51, 53.91, 108.68, 110.64, 110.45, 111.74, 115.89, 116.17, 119.13, 119.79, 120.63, 123.71, 123.82, 125.32, 126.34, 128.01, 129.42, 130.59, 130.70, 132.61, 132.65, 137.15, 140.08, 140.90, 141.45, 142.50, 144.43, 160.71, 161.86, 163.95, 177.66 ppm; **HRMS**: mass calculated for  $[C_{33}H_{21}ClFN_7O_2]^+$ : 602.1507  $[M + H]^+$ ; obs. mass: 602.1502  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-chloroindoline-3',4-chromene]pyrano[3,2-c]carbazole-3-carbonitrile, 6o**: brown solid; M.P.: 187–189 °C; **IR (KBr)**: 3307, 3184, 2923, 2190, 1777, 1705, 1650, 1608, 1487, 1454, 1335, 1216, 1107, 749  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  5.05 (br s, 2H, indolyl-CH<sub>2</sub>), 5.58 (s, 2H, benzylic-CH<sub>2</sub>), 6.42 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.10 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.23–7.29 (m, 5H, Ar-Hs), 7.39–7.45 (m, 4H, Ar-Hs), 7.47–7.54 (m, 1H, Ar-H), 7.65 (s, 2H, NH<sub>2</sub>), 8.10 (s, 1H, triazolyl-H), 8.56 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.57 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  35.78, 50.61, 52.52, 53.91, 108.65, 110.64, 111.47, 111.75, 119.13, 119.84, 120.60, 123.67, 123.73, 124.00, 125.29, 126.38, 128.03, 129.18, 129.44, 130.21, 130.34, 133.32, 135.32, 137.13, 140.07, 140.90, 142.51, 142.60, 144.42, 161.87, 177.62 ppm; **HRMS**: mass calculated for  $[C_{33}H_{21}Cl_2N_7O_2]^+$ : 618.1212  $[M + H]^+$ ; obs. mass: 618.1207  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(benzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-bromoindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6p**: brown solid; M.P.: 182–184 °C; **IR (KBr)**: 3308, 3174, 2933, 2180, 1767, 1715, 1640, 1618, 1485, 1451, 1335, 1216, 1109, 749  $cm^{-1}$ ; **<sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  5.04 (s, 2H, indolyl-CH<sub>2</sub>), 5.59 (s, 2H, benzylic-CH<sub>2</sub>), 6.40 (d, 1H,  $J = 8.0$  Hz, Ar-H), 6.99 (br s, 1H, Ar-H), 7.25–7.35 (m, 9H, Ar-Hs), 7.54 (d, 2H,  $J = 4.0$  Hz, Ar-Hs), 7.66 (s, 2H, NH<sub>2</sub>), 8.10 (s, 1H, triazolyl-H), 8.59 (d, 1H,  $J = 8.0$  Hz, Ar-H), 11.58 (s, 1H, NH); **<sup>13</sup>C NMR (75.4 MHz, DMSO-*d*<sub>6</sub>)**:  $\delta$  35.25, 50.04, 52.79, 53.37, 108.14, 110.11, 110.92, 111.73, 115.19, 118.59, 118.81, 119.26, 120.10, 123.14, 123.39, 125.82, 127.44, 127.76, 127.82, 128.07, 128.68, 131.72, 135.83, 137.00, 139.55, 140.36, 141.30,

143.85, 143.88, 161.32, 176.94 ppm; **HRMS**: mass calculated for  $[C_{33}H_{22}BrN_7O_2]$ : 628.1096  $[M + H]^+$ ; obs. mass: 628.1091  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-bromindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6q**: brown solid; M. P.: 202–204 °C; **IR (KBr)**: 3310, 3170, 2938, 2154, 1777, 1710, 1645, 1608, 1495, 1471, 1365, 1226, 1106, 753  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  2.26 (s, 3H, Ar-CH<sub>3</sub>), 4.99 (s, 2H, indoliny-CH<sub>2</sub>), 5.36 (dd, 2H,  $J = 19.5$  and 18.9 Hz benzylic-CH<sub>2</sub>), 6.37 (d, 1H,  $J = 8.1$  Hz, Ar-H), 7.02 (d, 2H,  $J = 8.4$  Hz, Ar-H), 7.05–7.09 (m, 4H, Ar-Hs), 7.18 (s, 2H, NH<sub>2</sub>), 7.33–7.38 (m, 3H, Ar-Hs), 7.42 (d, 2H,  $J = 8.1$  Hz, Ar-H), 7.83 (s, 1H, triazolyl-H), 8.51 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.26 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  21.19, 35.91, 50.52, 53.64, 54.17, 108.37, 108.45, 110.83, 111.10, 111.69, 115.85, 119.14, 119.53, 120.72, 123.27, 123.46, 123.64, 125.93, 127.90, 128.14, 129.61, 131.92, 132.60, 137.33, 138.00, 140.03, 140.93, 141.44, 144.46, 161.91, 177.43 ppm; **HRMS**: mass calculated for  $[C_{34}H_{24}BrN_7O_2]$ : 642.1253  $[M + H]^+$ ; obs. mass: 642.1248  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-bromindoline-3',4-chromene] pyrano[3,2-c] carbazole-3-carbonitrile, 6r**: brown solid; M.P.: 190–192 °C; **IR (KBr)**: 3320, 3174, 2959, 2191, 1710, 1715, 1652, 1625, 1451, 1335, 1216, 1021, 750  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  5.01 (s, 2H, indoliny-CH<sub>2</sub>), 5.50 (s, 2H, benzylic-CH<sub>2</sub>), 6.40 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.04–7.51 (m, 13H, 11-Ar-Hs, NH<sub>2</sub>), 7.98 (s, 1H, triazolyl-H), 8.55 (d, 1H,  $J = 7.2$  Hz, Ar-H), 11.38 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  35.86, 50.52, 50.80, 54.10, 108.32, 108.47, 110.81, 111.14, 111.75, 115.70, 115.85, 115.99, 119.15, 119.56, 120.71, 123.48, 123.65, 125.97, 127.90, 130.29, 130.40, 131.85, 131.96, 137.35, 140.03, 140.93, 141.48, 142.43, 144.46, 160.77, 161.91, 164.03, 177.45 ppm; **HRMS**: mass calculated for  $[C_{33}H_{21}BrFN_7O_2]$ : 646.1002  $[M + H]^+$ ; obs. mass: 646.0997  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-bromindoline-3',4-chromene] pyrano[3,2-c] carbazole-3-carbonitrile, 6s**: brown solid; M. P.: 185–187 °C; **IR (KBr)**: 3325, 3138, 2959, 2191, 1710, 1652, 1602, 1457, 1398, 1333, 1220, 1115, 1047, 749  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  5.03 (s, 2H, indoliny-CH<sub>2</sub>), 5.56 (s, 2H, benzylic-CH<sub>2</sub>), 6.42 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.07 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.16–7.50 (m, 10H, Ar-Hs), 7.58 (s, 2H, NH<sub>2</sub>), 8.06 (s, 1H, triazolyl-H), 8.55 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.47 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  35.80, 50.54, 52.61, 53.94, 108.49, 108.54, 110.73, 111.26, 112.02, 115.74, 119.12, 119.61, 120.69, 123.62, 123.71, 123.84, 126.08, 127.90, 129.07, 130.05, 132.08, 133.48, 135.05, 137.45, 140.06, 140.92, 141.71, 142.43, 144.45, 161.87, 177.43 ppm; **HRMS**: mass calculated for  $[C_{33}H_{21}BrClN_7O_2]$ : 662.0707  $[M + H]^+$ ; obs. mass: 662.0701  $[M + H]^+$ .

**2-Amino-4,7-dihydro-1'((1-(benzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-fluorindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6t**: brown solid; M. P.: 168–170 °C; **IR (KBr)**: 3328, 3148, 2951, 2198, 1717, 1657, 1612, 1458, 1398, 1338, 1227, 1105, 1049, 759  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  5.03 (dd, 2H,  $J = 24.6$  Hz, indoliny-CH<sub>2</sub>), 5.57 (s, 2H, benzylic-CH<sub>2</sub>), 6.37 (d, 1H,  $J = 8.7$  Hz, Ar-H), 7.06–7.54 (m, 12H, Ar-Hs), 7.63 (s, 2H, NH<sub>2</sub>), 8.07 (s, 1H, triazolyl-H), 8.56 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.56 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  35.78, 50.34, 53.34, 54.17, 108.63, 108.85, 110.63, 111.13, 111.24, 111.46, 112.81, 113.14, 115.74, 116.05, 119.15, 119.83, 120.60, 123.65, 123.87, 126.36, 128.29, 128.62, 129.22, 136.32, 136.92, 138.68, 140.07, 140.87, 142.58, 144.40, 158.04, 161.88, 177.84 ppm; **HRMS**: mass calculated for  $[C_{33}H_{22}FN_7O_2]$ : 568.1897  $[M + H]^+$  and 590.1717  $[M + Na]^+$ ; obs. mass: 568.1892  $[M + H]^+$  and 590.1711  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-fluorindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6u**: brown solid; M. P.: 175–178 °C; **IR (KBr)**: 3321, 3138, 2942, 2182, 1727, 1656, 1617, 1448, 1395, 1339, 1228, 1145,

1039, 755  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  2.29 (s, 3H, Ar-CH<sub>3</sub>), 4.95 (dd, 2H,  $J = 23.4$  Hz, indoliny-CH<sub>2</sub>), 5.50 (s, 2H, benzylic-CH<sub>2</sub>), 6.38 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.07–7.54 (m, 11H, Ar-Hs), 7.64 (s, 2H, NH<sub>2</sub>), 8.02 (s, 1H, triazolyl-H), 8.55 (d, 1H,  $J = 7.5$  Hz, Ar-H), 11.57 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  21.14, 35.86, 50.79, 53.36, 54.17, 108.51, 110.75, 110.90, 111.22, 112.58, 112.91, 115.51, 115.83, 119.14, 119.65, 120.67, 123.49, 123.61, 126.05, 128.20, 129.64, 132.80, 136.72, 136.82, 137.98, 138.38, 140.04, 140.91, 142.46, 144.44, 158.01, 161.20, 161.95, 177.84 ppm; **HRMS**: mass calculated for  $[C_{34}H_{24}FN_7O_2]$ : 582.2054  $[M + H]^+$  and 604.1874  $[M + Na]^+$ ; obs. mass: 582.2048  $[M + H]^+$  and 604.1868  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-fluorindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6v**: brown solid; M. P.: 180–182 °C; **IR (KBr)**: 3317, 2924, 2853, 2191, 1707, 1652, 1600, 1488, 1451, 1399, 1220, 1167, 1020, 786  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  5.01 (dd, 2H,  $J = 20.1$  and 21.0 Hz, indoliny-CH<sub>2</sub>), 5.55 (s, 2H, benzylic-CH<sub>2</sub>), 6.39 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.07–7.54 (m, 11H, Ar-Hs), 7.63 (s, 2H, NH<sub>2</sub>), 8.07 (s, 1H, triazolyl-H), 8.55 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.56 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  35.32, 50.33, 52.02, 53.59, 108.12, 108.40, 110.16, 110.95, 112.45, 115.29, 115.46, 115.63, 118.65, 119.26, 120.17, 123.21, 123.33, 125.82, 130.13, 130.20, 132.16, 136.43, 138.26, 139.60, 140.41, 142.15, 143.96, 158.20, 160.10, 160.88, 161.38, 162.82, 177.32 ppm; **HRMS**: mass calculated for  $[C_{33}H_{21}F_2N_7O_2]$ : 586.1803  $[M + H]^+$  and 608.1623  $[M + Na]^+$ ; obs. mass: 586.1798  $[M + H]^+$  and 608.1617  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-fluorindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6w**: brown solid; M.P.: 170–172 °C; **IR (KBr)**: 3310, 3164, 2930, 2185, 1757, 1705, 1645, 1608, 1485, 1459, 1385, 1216, 1129, 749  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  5.03 (br s, 2H, indoliny-CH<sub>2</sub>), 5.59 (s, 2H, benzylic-CH<sub>2</sub>), 6.43 (d, 1H,  $J = 7.8$  Hz, Ar-H), 7.09–7.54 (m, 11H, Ar-Hs), 7.64 (s, 2H, NH<sub>2</sub>), 8.11 (s, 1H, triazolyl-H), 8.56 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.57 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  35.79, 50.84, 52.65, 54.16, 108.63, 108.85, 110.63, 111.45, 115.74, 119.12, 119.79, 120.63, 123.67, 123.72, 124.00, 126.34, 129.18, 129.40, 130.22, 133.31, 135.36, 136.82, 136.90, 138.72, 140.08, 140.87, 142.64, 144.43, 158.16, 161.86, 177.81 ppm; **HRMS**: mass calculated for  $[C_{33}H_{21}ClFN_7O_2]$ : 602.1507  $[M + H]^+$  and 624.1327  $[M + Na]^+$ ; obs. mass: 602.1502  $[M + H]^+$  and 624.1322  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-benzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-methylindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6x**: brown solid; M.P.: 201–203 °C; **IR (KBr)**: 3318, 2933, 2180, 1767, 1715, 1640, 1618, 1485, 1451, 1335, 1216, 1109, 755  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  2.21 (s, 3H, Ar-CH<sub>3</sub>), 4.99 (dd, 2H,  $J = 27.0$  and 27.9 Hz, indoliny-CH<sub>2</sub>), 5.58 (s, 2H, benzylic-CH<sub>2</sub>), 6.35 (d, 1H,  $J = 8.3$  Hz, Ar-H), 6.96 (s, 1H, Ar-H), 7.03–7.51 (m, 11H, Ar-Hs), 7.56 (s, 2H, NH<sub>2</sub>), 8.06 (s, 1H, triazolyl-H), 8.57 (d, 1H,  $J = 8.1$  Hz, Ar-H), 11.55 (s, 1H, NH);  **$^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ )**:  $\delta$  20.99, 35.73, 50.41, 53.29, 54.67, 108.54, 109.58, 109.82, 110.54, 111.41, 119.32, 119.73, 120.64, 123.66, 123.76, 123.89, 125.63, 126.25, 128.32, 128.59, 129.21, 129.64, 132.99, 135.42, 136.42, 139.99, 140.06, 140.72, 142.83, 144.36, 161.73, 177.79 ppm; **HRMS**: mass calculated for  $[C_{34}H_{25}N_7O_2]$ : 564.2148  $[M + H]^+$  and 586.1968  $[M + Na]^+$ ; obs. mass: 564.2142  $[M + H]^+$  and 586.1962  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'oxo-spiro[5'-methylindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6y**: brown solid; M.P.: 268–270 °C; **IR (KBr)**: 3318, 3171, 2937, 2185, 1757, 1705, 1630, 1628, 1488, 1441, 1338, 1220, 1169, 752  $cm^{-1}$ ;  **$^1H$  NMR (300 MHz, DMSO- $d_6$ )**:  $\delta$  2.12 (s, 3H, Ar-CH<sub>3</sub>), 2.26 (s, 3H, Ar-CH<sub>3</sub>), 4.98 (br s, 2H, indoliny-CH<sub>2</sub>), 5.51 (s, 2H, benzylic-CH<sub>2</sub>), 6.36 (d, 1H,  $J = 8.4$  Hz, Ar-Hs), 6.95 (br s, 1H, Ar-H), 7.06–7.44 (m, 10H, Ar-Hs), 7.55 (s, 2H, NH<sub>2</sub>), 8.01 (s, 1H, triazolyl-H), 8.56 (d, 1H,  $J = 8.1$  Hz, Ar-H), 11.54 (s, 1H, NH);  **$^{13}C$  NMR**

(75.4 MHz, DMSO- $d_6$ ):  $\delta$  20.99, 21.15, 35.74, 50.41, 53.11, 54.67, 108.54, 109.58, 109.81, 110.55, 111.41, 119.33, 119.73, 120.64, 123.57, 123.66, 123.92, 125.63, 126.26, 128.37, 129.65, 129.73, 132.99, 133.38, 135.41, 137.43, 140.00, 140.07, 140.73, 142.79, 144.37, 161.74, 177.86 ppm; HRMS: mass calculated for  $[C_{35}H_{27}N_7O_2]$ : 578.2304  $[M + H]^+$  and 600.2124  $[M + Na]^+$ ; obs. mass: 578.2299  $[M + H]^+$  and 600.2118  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'-oxo-spiro[5'-methylindoline-3',4-chromene] pyrano[3,2-c]carbazole-3 carbonitrile, 6z:** brown solid; M.P.: 205–207 °C; IR (KBr): 3317, 2923, 2854, 2362, 2190, 1703, 1652, 1625, 1496, 1398, 1336, 1220, 1180, 1098, 809, 785, 750  $cm^{-1}$ ;  $^1H$  NMR (300 MHz, DMSO- $d_6$ ):  $\delta$  2.21 (s, 3H, Ar-CH<sub>3</sub>), 4.98 (dd, 2H,  $J = 24.0$  Hz, indolinyl-CH<sub>2</sub>), 5.57 (s, 2H, benzylic-CH<sub>2</sub>), 6.38 (d, 1H,  $J = 8.4$  Hz, Ar-H), 7.06–7.51 (m, 11H, Ar-Hs), 7.55 (s, 2H, NH<sub>2</sub>), 8.07 (s, 1H, triazolyl-H), 8.58 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.54 (s, 1H, NH);  $^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ ):  $\delta$  20.99, 35.74, 50.42, 52.49, 54.69, 108.54, 109.58, 109.81, 110.56, 111.42, 115.88, 116.17, 119.32, 119.73, 120.65, 123.71, 123.94, 125.65, 126.26, 129.65, 130.61, 130.72, 132.64, 133.00, 135.41, 140.01, 140.07, 140.75, 142.87, 144.39, 160.70, 161.74, 163.94, 177.81 ppm; HRMS: mass calculated for  $[C_{34}H_{24}FN_7O_2]$ : 582.2054  $[M + H]^+$  and 604.1874  $[M + Na]^+$ ; obs. mass: 582.2048  $[M + H]^+$  and 604.1868  $[M + Na]^+$ .

**2-Amino-4,7-dihydro-1'((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-2'-oxo-spiro[5'-methylindoline-3',4-chromene] pyrano[3,2-c]carbazole-3-carbonitrile, 6aa:** brown solid; M.P.: 190–192 °C; IR (KBr): 3308, 3174, 2933, 2180, 1767, 1715, 1640, 1618, 1485, 1451, 1335, 1216, 1109, 749  $cm^{-1}$ ;  $^1H$  NMR (300 MHz, DMSO- $d_6$ ):  $\delta$  2.21 (s, 3H, Ar-CH<sub>3</sub>), 5.00 (br s, 2H, indolinyl-CH<sub>2</sub>), 5.59 (s, 2H, benzylic-CH<sub>2</sub>), 6.39 (d, 1H,  $J = 8.4$  Hz, Ar-H), 6.96 (s, 1H, Ar-H), 7.11–7.53 (m, 10H, Ar-Hs), 7.56 (s, 2H, NH<sub>2</sub>), 8.08 (s, 1H, triazolyl-H), 8.58 (d, 1H,  $J = 7.8$  Hz, Ar-H), 11.54 (s, 1H, NH);  $^{13}C$  NMR (75.4 MHz, DMSO- $d_6$ ):  $\delta$  21.00, 35.72, 50.41, 52.47, 54.70, 108.54, 109.57, 109.81, 110.53, 111.41, 119.30, 119.72, 120.64, 123.66, 123.88, 123.95, 125.64, 126.25, 129.17, 129.18, 129.64, 130.24, 132.99, 133.29, 135.41, 140.00, 140.07, 140.74, 142.87, 144.38, 161.73, 177.80 ppm; HRMS: mass calculated for  $[C_{34}H_{24}FN_7O_2]$ : 598.1758  $[M + H]^+$  and 620.1578  $[M + Na]^+$ ; obs. mass: 598.1753  $[M + H]^+$  and 620.1572  $[M + Na]^+$ .

## Acknowledgments

P.V. Chavan wishes to thank University Grants Commission (UGC), New Delhi, India for the award of teacher fellowship. Dr. A.S. Choudhari is grateful to Science and Engineering Research Board (SERB), Government of India, New Delhi for the award of National Post-Doctoral Fellowship (N-PDF, File no: PDF/2016/003615). We gratefully acknowledge Dr. K. G. Kanade, Principal, Yashwantrao Chavan Institute of Science, Satara, for encouragement.

## Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bioorg.2019.01.070>.

## References

- E.A. Latif, S.A. Fattah, H.E. Gaffer, H.A. Etman, Synthesis and antitumor activity of some new pyrazolo[3,4-d]pyrimidine and pyrazolo[3,4-b]pyridine derivatives, *Egypt. J. Basic Appl. Sci.* 3 (2016) 118–123, <https://doi.org/10.1016/j.ejbas.2015.11.001>.
- D.S. Shewach, R.D. Kuchta, Introduction to cancer chemotherapeutics, *Chem. Rev.* 109 (2009) 2859–2861, <https://doi.org/10.1021/cr900208x>.
- F. Bray, B. Moller, Predicting the future burden of cancer, *Nat. Rev. Cancer.* 6 (2006) 63–74, <https://doi.org/10.1038/nrc1781>.
- D.C. Baquiran, J. Gallagher, *Cancer Chemotherapy Handbook, second ed.*, Lippincott Williams & Wilkins Publishers, 2001 ISBN: 978-0781726467.
- B.A. Chabner, T.G. Roberts Jr., Chemotherapy and the war on cancer, *Nat. Rev. Cancer* 5 (2005) 65–72, <https://doi.org/10.1038/nrc1529>.
- K. Nurgali, R.T. Jagoe, R. Abalo, Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? *Front. Pharmacol.* 9 (2018) 245, <https://doi.org/10.3389/fphar.2018.00245>.
- K. Kumar, S. Sagar, L. Easu, M. Kaur, V. Kumar, Synthesis of novel 1H-1,2,3-triazoles tethered C-5 substituted uracil-isatin conjugates and their cytotoxic evaluation, *Eur. J. Med. Chem.* 58 (2012) 153–159, <https://doi.org/10.1016/j.ejmech.2012.10.008>.
- K. Appalanaidu, R. Kotcherlakota, T.L. Dadmal, V.S. Bollu, R.M. Kumbhare, C.R. Patra, Synthesis and biological evaluation of novel 2-imino-4-thiazolidinone derivatives as potent anti-cancer agents, *Bioorg. Med. Chem. Lett.* 26 (2016) 5361–5368, <https://doi.org/10.1016/j.bmcl.2016.08.013>.
- V.L. Nayak, B. Nagaseshadri, M.V.P.S. Vishnuvardhan, Ahmed Kamal, Investigation of the apoptotic pathway induced by benzimidazole-oxindole conjugates against human breast cancer cells MCF-7, *Bioorg. Med. Chem. Lett.* 26 (2016) 3313–3317, <https://doi.org/10.1016/j.bmcl.2016.05.045>.
- S.S. Chauhan, A.K. Singh, S. Meena, M. Lohani, A. Singh, R.K. Arya, S.H. Cheruvu, J. Sarkar, J.R. Gayen, D. Datta, P.M.S. Chauhan, Synthesis of novel  $\beta$ -carboline based chalcones with high cytotoxic activity against breast cancer cells, *Bioorg. Med. Chem. Lett.* 24 (2014) 2820–2824, <https://doi.org/10.1016/j.bmcl.2014.04.109>.
- K.S. Atwal, J.R. McCullough, A. Hedberg, M.L. Conder, S.Z. Ahmed, G. Cucinotta, D.E. Normandin, The discovery of a novel calcium channel blocker related to the structure of potassium channel opener cromakalim, *Bioorg. Med. Chem. Lett.* 2 (1992) 1475–1478, [https://doi.org/10.1016/S0960-894X\(00\),80411-4](https://doi.org/10.1016/S0960-894X(00),80411-4).
- S.T. Hilton, T.C.T. Ho, G. Pljevaljcic, K. Jones, A new route to spirooxindoles, *Org. Lett.* 2 (2000) 2639–2641, <https://doi.org/10.1021/ol00061642>.
- M.H. Teiten, M. Dicato, M. Diederich, Hybrid curcumin compounds: a new strategy for cancer treatment, *Molecules* 19 (2014) 20839–20863, <https://doi.org/10.3390/molecules191220839>.
- N. Sharma, D. Mohankrishna, A. Shard, A. Sharma, A.K. Sinha, D. Sahal, Stilbene-chalcone hybrids: design, synthesis and evaluation as a new class of antimalarial scaffolds that trigger cell death through stage specific apoptosis, *J. Med. Chem.* 55 (2012) 297–311, <https://doi.org/10.1021/jm201216y>.
- L. Kumar, A. Jain, N. Lal, A. Sarswat, S. Jangir, L. Kumar, V. Singh, P. Shah, S.K. Jain, J.P. Maikhuri, M.I. Siddiqi, G. Gupta, V.L. Sharma, Potentiating metronidazole scaffold against resistant trichomonas: design, synthesis, biology and 3D-QSAR analysis, *ACS Med. Chem. Lett.* 3 (2012) 83–87, <https://doi.org/10.1021/ml200161t>.
- V. Bala, S. Jangir, D. Mandalapu, S. Gupta, Y.S. Chhonkar, N. Lal, B. Kushwaha, H. Chandasana, S. Krishna, K. Rawat, J.P. Maikhuri, R.S. Bhatt, M.I. Siddiqi, R. Tripathi, G. Gupta, V.L. Sharma, Dihydrocarbamate-thiourea hybrids useful as vaginal microbicides also show reverse transcriptase inhibition: design, synthesis, docking and pharmacokinetic studies, *Bioorg. Med. Chem. Lett.* 25 (2015) 881–886, <https://doi.org/10.1016/j.bmcl.2014.12.062>.
- K.S. Pandit, R.V. Kupwade, P.V. Chavan, U.V. Desai, P.P. Wadgaonkar, K.M. Kodam, Problem solving and environmentally benign approach toward diversity oriented synthesis of novel 2-amino-3-phenyl (or Alkyl) sulfonyl-4H-chromenes at ambient temperature, *ACS Sustain. Chem. Eng.* 4 (2016) 3450–3464, <https://doi.org/10.1021/acssuschemeng.6b00484>.
- K.S. Pandit, P.V. Chavan, U.V. Desai, M.A. Kulkarni, P.P. Wadgaonkar, Tris-hydroxymethylaminomethane (THAM): a novel organocatalyst for an environmentally benign synthesis of medicinally important tetrahydrobenzo[b]pyrans and pyran-annulated heterocycles, *New J. Chem.* 39 (2015) 4452–4463, <https://doi.org/10.1039/C4NJ02346C>.
- A.M. Kulkarni, K.S. Pandit, P.V. Chavan, U.V. Desai, P.P. Wadgaonkar, Cobalt ferrite nanoparticles: a magnetically separable and reusable catalyst for Patisis-Borono-Mannich reaction, *RSC Adv.* 5 (2015) 70586–70594, <https://doi.org/10.1039/C5RA10693A>.
- P.V. Chavan, K.S. Pandit, U.V. Desai, P.P. Wadgaonkar, L. Nawale, S. Bhansali, D. Sarkar, Click-chemistry-based multicomponent condensation approach for design and synthesis of spirochromene-tethered 1,2,3-triazoles as potential anti-tubercular agents, *Res. Chem. Intermed.* 43 (2017) 5675–5690, <https://doi.org/10.1007/s11164-017-2955-y>.
- B. Maryam, B. Afifa, S.I. Abdul, A.C. Bashir, Recent developments and biological activities of N-substituted carbazole derivatives: a review, *Molecules* 20 (2015) 13496–13517, <https://doi.org/10.3390/molecules200813496>.
- K.N. Mounika, A.N. Jyothi, G.N. Raju, R.R. Nadendla, Carbazole derivatives in cancer treatment, *World J. Phar. Pharm. Sci.* 4 (2015) 420–428.
- A.W. Schmidt, K.R. Reddy, H.-J. Knolker, Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids, *Chem. Rev.* 112 (2012) 3193–3328, <https://doi.org/10.1021/cr200447s>.
- P. Narayana Reddy, P. Padmaja, Applications of aminocarbazoles in heterocyclic synthesis, *ARKIVOC* (i) (2015) 244–268, <https://doi.org/10.3998/ark.5550190.P008.822>.
- A. Gluzynska, Biological potential of carbazole derivatives, *Eur. J. Med. Chem.* 94 (2015) 405–426, <https://doi.org/10.1016/j.ejmech.2015.02.059>.
- P. Padmaja, G.K. Rao, A. Indrasena, B.V. Subba Reddy, N. Patel, A.B. Shaikh, N. Reddy, P.K. Dubey, M.P. Bhadra, Synthesis and biological evaluation of novel pyrano[3,2-c]carbazole derivatives as anti-tumor agents inducing apoptosis via tubulin polymerization inhibition, *Org. Biomol. Chem.* 13 (2015) 1404–1414, <https://doi.org/10.1039/C4OB02015D>.
- T. Indumathi, V.S. Jamal Ahamed, S.S. Moon, F.R. Fronczek, K.J. Rajendra Prasad, L-Proline anchored multicomponent synthesis of novel pyrido [2,3-a] carbazoles; investigation of *in vitro* antimicrobial, antioxidant, cytotoxicity and structure activity relationship studies, *Eur. J. Med. Chem.* 46 (2011) 5580–5590, <https://doi.org/10.1016/j.ejmech.2011.09.024>.
- T. Thongthoom, P. Promsuwan, C. Yenjai, Synthesis and cytotoxic activity of the heptaphylline and 7-methoxyheptaphylline series, *Eur. J. Med. Chem.* 46 (2011) 3755–3761, <https://doi.org/10.1016/j.ejmech.2011.05.041>.
- C. Guillonnet, A. Nault, E. Raimbaud, S. Leonce, L.K. Berther, A. Pierre, S. Goldstein, Cytotoxic and antitumor properties in a series of new, ring D

- modified, olivacine analogues, *Bioorg. Med. Chem.* 13 (2005) 175–184, <https://doi.org/10.1016/j.bmc.2004.09.047>.
- [30] T. Taj, R.R. Kamble, T.M. Gireesh, R.K. Hunnur, S.B. Margankop, One-pot synthesis of pyrazoline derivatized carbazoles as antitubercular, anticancer agents, their DNA cleavage and antioxidant activities, *Eur. J. Med. Chem.* 46 (2011) 4366–4373, <https://doi.org/10.1016/j.ejmech.2011.07.007>.
- [31] G.M. Dumitriu, A. Ghinet, D. Belei, B. Rigo, P. Gautret, J. Dubois, E. Bicu, Investigation of new phenothiazine and carbazole derivatives as potential inhibitors of human farnesyl transferase, *Lett. Drug Des. Discov.* 12 (2015) 85–92, <https://doi.org/10.2174/1570180811666140909010435>.
- [32] H. Kaur, S. Kumar, P. Vishwakarma, M. Sharma, K.K. Saxena, A. Kumar, Synthesis and antipsychotic and anticonvulsant activity of some new substituted oxa/thiazolidinonyl/thiazolidinonyl carbazoles, *Eur. J. Med. Chem.* 45 (2010) 2777–2783, <https://doi.org/10.1016/j.ejmech.2010.02.060>.
- [33] P. Thirumurugan, D. Matosiuk, K. Jozwiak, Click chemistry for drug development and diverse chemical – biology applications, *Chem. Rev.* 113 (2013) 4905–4979, <https://doi.org/10.1021/cr200409f>.
- [34] N. Boechat, V.F. Ferreira, S.B. Ferreira, M.D.L.G. Ferreira, F.D.C. da Silva, M.M. Bastos, M.D.S. Costa, M.C.S. Lourenço, A.C. Pinto, A.U. Krettl, A.C. Aguiar, B.M. Teixeira, N.V. da Silva, P.R.C. Martins, F.A.F.M. Bezerra, A.L.S. Camilo, G.P. da Silva, C.C.P. Costa, Novel 1,2,3-triazole derivatives for use against mycobacterium tuberculosis H37Rv (ATCC 27294) strain, *J. Med. Chem.* 54 (2011) 5988–5999, <https://doi.org/10.1021/jm2003624>.
- [35] G.I. Wei, W. Luan, S. Wang, S. Cui, F. Li, Y. Liu, M. Cheng, A library of 1,2,3-triazole-substituted oleanolic acid derivatives as anticancer agents: design, synthesis, and biological evaluation, *Org. Biomol. Chem.* 13 (2015) 1507–1514, <https://doi.org/10.1039/C4OB01605J>.
- [36] D. Mandalapu, K.S. Saini, S. Gupta, V. Sharma, M.Y. Malik, S. Chaturvedi, V. Bala, S. Hamidullah, J.P. Thakur, M. Maikhuri, R. Wahajuddin, G. Konwar, V.L. Gupta, Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines, *Bioorg. Med. Chem. Lett.* 26 (2016) 4223–4232, <https://doi.org/10.1016/j.bmcl.2016.07.053>.
- [37] X.L. Wang, K. Wan, C.H. Zhou, Synthesis of novel sulfanilamide-derived 1,2,3-triazoles and their evaluation for antibacterial and antifungal activities, *Eur. J. Med. Chem.* 45 (2010) 4631–4639, <https://doi.org/10.1016/j.ejmech.2010.07.031>.
- [38] D.R. Buckle, D.J. Outred, C.J.M. Rockell, H. Smith, B.A. Spicer, Studies on v-triazoles. 7. Antiallergic 9-oxo-1H,9H-benzopyrano[2,3-d]-v-triazoles, *J. Med. Chem.* 26 (1983) 251–254, <https://doi.org/10.1021/jm00356a025>.
- [39] Y. Xia, Z. Fan, J. Yao, Q. Liao, W. Li, F. Qu, L. Peng, Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus, *Bioorg. Med. Chem. Lett.* 16 (2006) 2693–2698, <https://doi.org/10.1016/j.bmcl.2006.02.023>.
- [40] R. Romeo, C. Carnovale, S.V. Giofrè, M.A. Chiacchio, A. Garozzo, E. Amata, G. Romeo, U. Chiacchio, C-5'-Triazolyl-2'-oxa-3'-aza-4'-a-carbanucleosides: synthesis and biological evaluation, *Beilstein J. Org. Chem.* 11 (2015) 328–334, <https://doi.org/10.3762/bjoc.11.38>.
- [41] N. Sunduru, K. Srivastava, S. Rajakumar, S.K. Puri, J.K. Saxena, P.M. Chauhan, Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials, *Bioorg. Med. Chem. Lett.* 19 (2009) 2570–2573, <https://doi.org/10.1016/j.bmcl.2009.03.026>.
- [42] M.J. Giffin, H. Heaslet, A. Brik, Y.C. Lin, G. Cauvi, C.H. Wong, D.E. McRee, J.H. Elder, C.D. Stout, B.E. Torbett, A Copper(I)-catalyzed 1,2,3-triazole azide – alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant, *J. Med. Chem.* 51 (2008) 6263–6270, <https://doi.org/10.1021/jm800149m>.
- [43] D. Caprioglio, S. Torretta, M. Ferrari, C. Travelli, A.A. Grolla, F. Condorelli, A.A. Genazzani, A. Minassi, Triazole-curcuminoids: a new class of derivatives for 'tuning' curcumin bioactivities? *Bioorg. Med. Chem.* 24 (2016) 140–152, <https://doi.org/10.1016/j.bmc.2015.11.044>.
- [44] N.R. Madadi, N.R. Penthalala, K. Howk, A. Ketkar, R.Z. Eoff, M.J. Borrelli, P.A. Crooks, Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4, *Eur. J. Med. Chem.* 103 (2015) 123–132, <https://doi.org/10.1016/j.ejmech.2015.08.041>.
- [45] S. Sharma, M.K. Gupta, A.K. Saxena, P.M. Bedi, Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: design, synthesis, biological evaluation and molecular modeling studies, *Bioorg. Med. Chem.* 23 (2015) 7165–7180, <https://doi.org/10.1016/j.ejmech.2015.08.041>.
- [46] J. Khazir, I. Hyder, J.L. Gayatri, L.P. Yandradi, N. Nalla, G. Chasoo, A. Mahajan, A.K. Saxena, M.S. Alam, G.N. Qazi, K.H. Samoath, Design and synthesis of novel 1,2,3-triazole derivatives of coronopilin as anti-cancer compounds, *Eur. J. Med. Chem.* 82 (2014) 255–262, <https://doi.org/10.1016/j.ejmech.2014.05.053>.
- [47] Y.C. Duan, Y.C. Zheng, X.C. Li, M.M. Wang, X.W. Ye, Y.Y. Guan, G.Z. Liu, J.X. Zheng, H.M. Liu, Design synthesis and antiproliferative activity studies of novel 1,2,3-triazole-dithiocarbamate-urea hybrids, *Eur. J. Med. Chem.* 64 (2013) 99–110, <https://doi.org/10.1016/j.ejmech.2013.03.058>.
- [48] J.A. Stefely, R. Patchaudhari, P.A. Miller, R.J. Peterson, G.C. Moraski, P.J. Hergenrother, M.J. Miller, N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl) arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines, *J. Med. Chem.* 53 (2010) 3389–3395, <https://doi.org/10.1021/jm1000979>.
- [49] X. Li, Y. Lin, Q. Wang, Y. Yuon, H. Zhang, X. Qian, The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage, *Eur. J. Med. Chem.* 46 (2011) 1274–1279, <https://doi.org/10.1016/j.ejmech.2011.01.050>.
- [50] M.J. Soltis, H.J. Yeh, K.A. Cole, N. Whittaker, R.P. Wersto, E.C. Kohn, Identification and characterization of human metabolites of CAI [5-amino-1-(4'-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide, *Drug. Metab. Dispos.* 24 (1996) 799–806.
- [51] K.L. Vine, L. Matesic, J.M. Locke, D. Skropeta, Recent highlights in the development of isatin – based anticancer agents, in: M. Prudhomme (Ed.), *Advances in Anticancer Agents in Medicinal Chemistry*, Bentham Science Publishers, Sharjah, UAE, 2013, pp. 254–312.
- [52] P.V. Chavan, K.S. Pandit, U.V. Desai, M.A. Kulkarni, P.P. Wadgaonkar, Cellulose supported cuprous iodide nanoparticles (Cell-CuI NPs): a new heterogeneous and recyclable catalyst for the one pot synthesis of 1,4-disubstituted-1,2,3-triazoles in water, *RSC Adv.* 4 (2014) 42137–42146, <https://doi.org/10.1039/C4RA05080K>.
- [53] N.K. Rasal, R.B. Sonawane, A.S. Choudhari, S.S. Chakraborty, D.D. Sarkar, S.V. Jagtap, Novel 2,4-dimethyl-5-((E)-3-phenyl-3-oxoprop-1-enyl)-1H-pyrrole-3-carboxylic acid derivatives: new leads in cancer and bacterial chemotherapy, *Chem. Sel.* 3 (2018) 9571–9575, <https://doi.org/10.1002/slct.201801458>.